伊曲康唑治疗血液病合并侵袭性真菌病9例疗效分析

Utility of intraconazole in treatment of invasive fungal infections of haematological patients

目的探讨伊曲康唑对在血液病合并侵袭性真菌病(IFI)患者的疗效及不良反应。方法2005年3月至2007年3月对上海交通大学附属仁济医院血液科收治的9例血液病合并侵袭性真菌病患者予以伊曲康唑静脉及口服治疗,根据临床症状和体征、真菌镜检等判定患者的疗效及不良反应。结果经伊曲康唑辅以综合治疗有效率达89%(8/9),其中痊愈7例,显效1例;1例患者因肺部体征继续进展导致呼吸衰竭死亡。未发生不能耐受的毒副反应。结论伊曲康唑在血液病合并侵袭性真菌病患者治疗中安全有效。

Objective To evaluate the clinical efficacy and safety of intravenous itraconazole in treatment of invasive fungal infected patients with haematological desease. Methods From March 2005 to March 2007,9 cases of blood disease complicated by invasive fungal inffections in Renji Hospital were treated with intravenous and oral intraconazole. Clinical efficacy and side effects were observed according to the clinical signs and symptoms and fungal scopy. Results After intraeonazole assisted by comprehensive treatment：the total effectiveness rate was 89%. Among 9 cases,7 achieved total recovery, 1 effective and one dead due to respiratory failure caused by pulmonary progression. There were no untoleranted side effects. Conclusion hraconazole is an effective and safe choice for the treatment of invasive fungal infections.